Trials / Completed

CompletedNCT05063539

A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease

Assessment of Safety, Tolerability, and Efficacy of LY3372689 in Early Symptomatic Alzheimer's Disease

Status: Completed
Phase: Phase 2
Study type: Interventional
Enrollment: 327 (actual)

Sponsor: Eli Lilly and Company · Industry
Sex: All
Age: 60 Years – 85 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to assess the safety, tolerability and effect of study drug LY3372689 in participants with early symptomatic Alzheimer's Disease

Conditions

Alzheimer Disease

Interventions

Type	Name	Description
DRUG	LY3372689	given orally
DRUG	LY3372689	given orally
DRUG	Placebo	given orally

Timeline

Start date: 2021-09-16
Primary completion: 2024-07-09
Completion: 2025-05-22
First posted: 2021-10-01
Last updated: 2025-07-28
Results posted: 2025-07-28

Locations

69 sites across 5 countries: United States, Australia, Canada, Japan, Poland

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT05063539. Inclusion in this directory is not an endorsement.